This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Palatin Technologies, Inc. Announces Presentation And Publication On Validation Of Scale For Subjective Male Sexual Arousal

CRANBURY, N.J., June 15, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications, announced presentation and publication of a report on validation of a scale for subjective male sexual arousal.  The underlying study was supported by grants from Palatin.

Michael A. Perelman, Ph.D., of the New York Presbyterian Hospital and the Weill Medical College of Cornell University, presented the poster on June 13, 2011 at the 20th World Congress for Sexual Health in Glasgow, United Kingdom.  The paper, entitled "The Subjective Sexual Arousal Scale for Men (SSASM): Preliminary Development and Psychometric Validation of a Multidimensional Measure of Subjective Male Sexual Arousal," has been published in the online version of the Journal of Sexual Medicine and will appear in a forthcoming print issue. Stanley E. Althof, Ph.D., Executive Director of the Center for Marital and Sexual Health of South Florida and Emeritus Professor, Case Western Reserve University School of Medicine, and Raymond C. Rosen, Ph.D., of New England Research Institutes, are co-authors on the paper with Dr. Perelman.

The presentation and paper describe development and psychometric validation of a self-administered scale for assessing subjective male sexual arousal.  Based upon recommendations of the Food and Drug Administration guidance on patient-reported outcome instruments, important aspects of male sexual arousal were identified through qualitative research of U.S. men with erectile dysfunction and healthy controls.

The Subjective Sexual Arousal Scale for Men (SSASM) may be useful in drug development for treatment of erectile dysfunction.  The SSASM is the first validated research instrument with a focus on assessing subjective male sexual arousal in men with erectile dysfunction in a clinical trial setting.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,654.77 +369.26 2.27%
S&P 500 1,987.66 +47.15 2.43%
NASDAQ 4,812.7080 +115.1720 2.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs